Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of MYO-029 in Adult Muscular Dystrophy
NCT00104078Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stamulumab in Becker muscular dystrophy (BMD), facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), sponsored by Pfizer. Started Feb 2005; status: completed.
02
Drugs
stamulumab
03
Conditions
Becker muscular dystrophy (BMD)facioscapulohumeral muscular dystrophy (FSHD)limb-girdle muscular dystrophy (LGMD)
Beyond the preview
Go deeper on NCT00104078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104078.